Genomic and Proteomic Biomarkers for Head and Neck Cancer Risk and Prognosis

头颈癌风险和预后的基因组和蛋白质组生物标志物

• 批准号: 8327244
• 负责人: ANN MARIE EGLOFF
• 金额: $ 10.52万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-04 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8327244
• 关键词: Address; Affect; Age; Archives; Biological Markers; Bombesin Receptor; Cancer Patient; Cancer Prognosis; Case-Control Studies; Characteristics; Clinical; DNA; Data; Data Collection; Development; Development Plans; Disease; Disease Progression; Doctor of Philosophy; Environmental Exposure; Epidemiologist; Epidermal Growth Factor Receptor; Ethnic Origin; Etiology; Frequencies; G-Protein-Coupled Receptors; GRP gene; Gender; Genetic; Genetic Polymorphism; Genetic Transcription; Genomics; Genotype; Goals; Haplotypes; Head Cancer; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Histologic; Individual; Instruction; Logistic Regressions; Malignant Neoplasms; Mentors; Messenger RNA; Modeling; Molecular; Monitor; Mucous Membrane; Otolaryngology; Pathologic; Patients; Phosphoproteins; Populations at Risk; Proteins; Proteomics; Receptor Gene; Receptor Signaling; Reporting; Research Design; Research Personnel; Resources; Risk; Risk Factors; Signal Transduction Pathway; Smoking; Technology; Testing; Tobacco use; Training; Translational Research; Tumor Tissue; Universities; Update; Variant; age effect; alcohol exposure; cancer epidemiology; cancer genetics; cancer risk; career development; case control; conventional therapy; design; disorder control; experience; follow-up; genetic variant; improved; insight; malignant mouth neoplasm; outcome forecast; overexpression; peripheral blood; professor; prognostic; prognostic indicator; programs; receptor expression; response; sample collection; sex; tobacco exposure; tumor

Defining head and neck squamous cell carcinoma (HNSCC) prognostic and predictive biomarkers is anticipated to provide insights Into molecular contributors to disease progression and to contribute to HNSCC disease control. An ongoing effort by the Head and Cancer Program at the University of Pittsburgh has collected peripheral blood DNA from HNSCC cases and controls and demographic and tobacco use data beginning In 2000; tumor tissues have also been archived. Clinical, pathologic, and follow-up data continues to be collected for these 790 HNSCC cases. In addition to this large specimen and data collection, we have high-through-put genomic and proteomic technologies and expertise. We are therefore uniquely poised to evaluate biomarkers associated with HNSCC risk and prognosis. Epidermal growth factor receptor (EGFR) and gastrin-releasing peptide receptor (GRPR) are strongly implicated In HNSCC development/progression. Dr. Egloff proposes to: (1) determine whether EGFR/GRPR genetic variants are related to developing HNSCC using a case-control study; (2) determine whether EGFR/GRPR polymorphisms are prognostic indicators for HNSCC; and (3) evaluate correlations between HNSCC protein levels and EGFR/GRP R variant genotypes. These studies will be carried out with a carefully selected team of mentors and advisors who will provide expertise and guidance covering all aspects of the proposed studies. Dr. Egloff is an Assistant Professor in the Department of Otolaryngology, University of Pittsburgh with experience in translational research and formal training in cancer epidemiology and genetics. The candidate has outlined a career development plan including formal training in statistical genetics designed to facilitate her transition to an independent molecular epidemiologist cancer researcher. RELEVANCE (See instructions): The proposed studies will test the overall hypothesis that EGFR and GRPR genetic variants contribute to HNSCC risk and disease progression and are designed to gain insights into the molecular etiology of HNSCC and to define populations at risk for developing HNSCC and/or worse disease prognosis. Results of these studies are anticipated to inform treatment decisions and contribute significantly to HNSCC disease control.

定义头颈部鳞状细胞癌（HNSCC）预后和预测性生物标志物是 预计可以洞悉疾病进展的分子贡献者，并有助于 HNSCC疾病控制。匹兹堡大学负责人和癌症计划的持续努力 已从HNSCC病例和对照组以及人群和烟草使用中收集了外周血DNA 数据从2000年开始；肿瘤组织也已存档。临床，病理和随访数据 在这790个HNSCC病例中继续收集。除了这个大型标本和数据收集外， 我们具有高通用的基因组和蛋白质组学技术和专业知识。因此，我们是独特的 准备评估与HNSCC风险和预后相关的生物标志物。 表皮生长因子受体（EGFR）和胃蛋白释放肽受体（GRPR）强烈 与HNSCC的开发/进展有关。 Egloff博士提议：（1）确定EGFR/GRPR是否是否 遗传变异与使用病例对照研究开发HNSCC有关。 （2）确定是否 EGFR/GRPR多态性是HNSCC的预后指标； （3）评估相关性 HNSCC蛋白水平和EGFR/GRP R变体基因型。这些研究将仔细地进行 选定的导师和顾问团队将提供专业知识和指导，涵盖 拟议的研究。 Egloff博士是匹兹堡大学耳鼻喉科学系的助理教授 在癌症流行病学和遗传学方面的转化研究和正式培训方面的经验。候选人 概述了一项职业发展计划，包括旨在促进的统计遗传学的正式培训 她向独立的分子流行病学家癌症研究员过渡。 相关性（请参阅说明）： 拟议的研究将检验总体假设，即EGFR和GRPR遗传变异有助于 HNSCC风险和疾病进展，旨在洞悉 HNSCC并定义有患HNSCC和/或疾病预后的风险的人群。结果 预计这些研究将为治疗决定提供信息，并为HNSCC疾病做出重大贡献 控制。